We are live on ! Find out more
VTYX

Ventyx Biosciences
VTYX

Delisted

VTYX was delisted on the 3rd of March, 2026.

Back to rankings

63 hedge funds and large institutions have $408M invested in Ventyx Biosciences in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

15% more funds holding

Funds holding: 55 → 63 (+8)

2.59% more ownership

Funds ownership: 65.51% → 68.1% (+2.6%)

9% less capital invested

Capital invested by funds: $448M → $408M (-$40.7M)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
1.06%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
13
Increased
26
Reduced
13
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$11.3M
2
BlackRock
BlackRock
New York
+$8.46M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.43M
4
State Street
State Street
Massachusetts
+$2.3M
5
HighTower Advisors
HighTower Advisors
Illinois
+$2.28M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$9.05M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$3.42M
3
LGM
Logos Global Management
California
-$3.01M
4
FCM
Farallon Capital Management
California
-$2.74M
5
Millennium Management
Millennium Management
New York
-$1.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
51
STRS Ohio
Ohio
$29K – – –
UBS Group
52
UBS Group
Switzerland
$25K -$12.2K -816 -28%
TRCT
53
Tower Research Capital (TRC)
New York
$22K +$12.7K +852 +89%
AIP
54
Ameritas Investment Partners
Nebraska
$20K +$13.1K +874 +108%
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$18.5K +$22.6K +1,512 New
O
56
OrbiMed
New York
$15.8K – – –
HNWAG
57
High Net Worth Advisory Group
Florida
$6K +$2.99K +200 +67%
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$2K -$7.68K -514 -80%
PNC Financial Services Group
59
PNC Financial Services Group
Pennsylvania
$2K +$2.9K +194 New
QCG
60
Quadrant Capital Group
Ohio
$1K -$568 -38 -38%
Millennium Management
61
Millennium Management
New York
– -$1.19M -87,706 Closed
PI
62
Putnam Investments
Massachusetts
– -$216K -15,942 Closed
PHK
63
Point72 Hong Kong
Hong Kong
– -$16K -1,175 Closed
Carson Wealth (CWM LLC)
64
Carson Wealth (CWM LLC)
Nebraska
– +$224 +15 New
CS
65
Credit Suisse
Switzerland
– +$254 +17 New
1 2
3

VTYX Hedge Fund Activity: Q2 2022 in Review

63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2022, worth a combined $408M — down 9.1% from $448M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new VTYX positions and 4 closed out — a net gain of 9 holders — while 26 added to existing stakes and 13 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $11.3M. The largest seller was Wellington Management Group, cutting an estimated $9.05M.

  • 63 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2022, up from 55 in Q1 2022.
  • Funds reported $408M of Ventyx Biosciences stock for Q2 2022, down 9.1% quarter-over-quarter.
  • 13 funds opened new Ventyx Biosciences positions in Q2 2022 and 4 closed out, a net change of +9 holders.
  • The largest Ventyx Biosciences buyer in Q2 2022 was Fidelity Investments, an estimated $11.3M added.
  • The largest Ventyx Biosciences seller in Q2 2022 was Wellington Management Group, an estimated $9.05M sold.

Based on aggregated 13F filings for Q2 2022.